Beranda › Kanker Paru Non-Sel Kecil › Illinois › Joliet
Uji klinis Kanker Paru Non-Sel Kecil di Joliet, IL
12 studi untuk Kanker Paru Non-Sel Kecil mencari peserta di lokasi sekitar Joliet (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Menerima pesertaFase 3
- UC Comprehensive Cancer Center at Silver Cross, New Lenox · 6 mi jauhnya
- University of Chicago Medicine-Orland Park, Orland Park · 14 mi jauhnya
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Menerima pesertaFase 3
- Northwestern Medicine Orland Park, Orland Park · 14 mi jauhnya
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Menerima pesertaFase 3
- Hope and Healing Cancer Services, New Lenox · 6 mi jauhnya
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
Menerima pesertaFase 2
- Hope and Healing Clinical Research, New Lenox · 6 mi jauhnya
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
Menerima pesertaFase 3
- Hope and Healing Cancer Services, New Lenox · 6 mi jauhnya
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Menerima pesertaFase 1
- University of Chicago, New Lenox · 6 mi jauhnya
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Menerima pesertaFase 3
- Northwestern Medicine Orland Park, Orland Park · 14 mi jauhnya
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Menerima pesertaFase 1
- University of Chicago Comprehensive Cancer Center at Silver Cross Hospital, New Lenox · 6 mi jauhnya
- The University of Chicago Medicine Center for Advanced Care Orland Park, Orland Park · 14 mi jauhnya
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Menerima pesertaFase 2
- Northwestern Medicine Orland Park, Orland Park · 14 mi jauhnya
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Menerima pesertaFase 2
- Northwestern Medicine Orland Park, Orland Park · 14 mi jauhnya
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Menerima pesertaFase 2
- Northwestern Medicine Orland Park, Orland Park · 14 mi jauhnya
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Menerima pesertaFase 2/3
- Northwestern Medicine Orland Park, Orland Park · 14 mi jauhnya
Uji klinis Kanker Paru Non-Sel Kecil di kota lain
- Houston, TX145 studi
- New York City, NY120 studi
- Arlington, VA104 studi
- Nashville, TN97 studi
- Boston, MA90 studi
- Los Angeles, CA87 studi
- St. Louis, MO73 studi
- Chicago, IL61 studi
- Baltimore, MD60 studi
- San Antonio, TX59 studi
- Columbus, OH56 studi
- Washington, DC55 studi
Studi lain di Joliet
- Kanker Paru12 studi
- Kanker Metastatik7 studi
- Kanker Kandung Kemih7 studi
- Karsinoma Sel Skuamosa Kepala dan Leher6 studi
- Kanker Prostat5 studi
- Kanker Hipofaring5 studi
- Kanker Laring5 studi
- Kanker Mulut5 studi
- Leukemia Mieloid Akut5 studi
- Kanker Payudara4 studi
- Kanker Kolon4 studi
- Kanker Ginjal (Karsinoma Sel Renal)4 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.